Alligator Bioscience and Aptevo Therapeutics: Unveiling More Positive Data for ALG.APV-527 at SITC 2024
Tuesday, Oct 29, 2024 11:41 am ET
1min read Alligator Bioscience and Aptevo Therapeutics are set to present additional positive interim Phase 1 data evaluating ALG.APV-527 monotherapy in multiple solid tumor types at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in 2024. This promising development highlights the potential of ALG.APV-527 as a novel bispecific immunotherapy for cancer treatment.
ALG.APV-527 is a conditional 4-1BB agonist, designed to stimulate immune cells involved in tumor control while minimizing systemic immune activation. The drug is being investigated in a multi-center, multi-cohort, open-label dose-escalation trial, enrolling adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen.
The interim data to be presented at SITC 2024 builds upon the positive results announced earlier in 2024. The drug has shown favorable drug exposure, confirming its biological activity, and has demonstrated early signs of clinical activity in heavily pre-treated patients. Notably, two patients with heavily pre-treated breast cancer achieved stable disease, with one patient remaining on the study for seven months and the other for over nine months.
The positive interim data supports the potential of ALG.APV-527 in treating solid tumors, as it has shown promising safety, pharmacokinetics, and pharmacodynamics profiles. The drug's ability to target both 4-1BB and 5T4 antigens makes it a compelling candidate for cancer immunotherapy. As the trial progresses, continued analysis of various tumor types will offer valuable insights into ALG.APV-527's potential for later-stage development.
The presentation of additional positive interim data at SITC 2024 underscores the potential of ALG.APV-527 as a novel bispecific immunotherapy for cancer treatment. As the trial continues, investors can expect further updates on the drug's progress and potential market acceptance. With the growing interest in cancer immunotherapy and the need for innovative treatments, ALG.APV-527 holds promise for transforming the lives of cancer patients.
ALG.APV-527 is a conditional 4-1BB agonist, designed to stimulate immune cells involved in tumor control while minimizing systemic immune activation. The drug is being investigated in a multi-center, multi-cohort, open-label dose-escalation trial, enrolling adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen.
The interim data to be presented at SITC 2024 builds upon the positive results announced earlier in 2024. The drug has shown favorable drug exposure, confirming its biological activity, and has demonstrated early signs of clinical activity in heavily pre-treated patients. Notably, two patients with heavily pre-treated breast cancer achieved stable disease, with one patient remaining on the study for seven months and the other for over nine months.
The positive interim data supports the potential of ALG.APV-527 in treating solid tumors, as it has shown promising safety, pharmacokinetics, and pharmacodynamics profiles. The drug's ability to target both 4-1BB and 5T4 antigens makes it a compelling candidate for cancer immunotherapy. As the trial progresses, continued analysis of various tumor types will offer valuable insights into ALG.APV-527's potential for later-stage development.
The presentation of additional positive interim data at SITC 2024 underscores the potential of ALG.APV-527 as a novel bispecific immunotherapy for cancer treatment. As the trial continues, investors can expect further updates on the drug's progress and potential market acceptance. With the growing interest in cancer immunotherapy and the need for innovative treatments, ALG.APV-527 holds promise for transforming the lives of cancer patients.
Comments
No Comment Yet
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
_56ef5cf71747658846645.jpeg)
